Biogen (BIIB) Finished Goods (2010 - 2018)
Biogen (BIIB) recorded quarterly Finished Goods of $133.5 million in Q4 2018, down 15.18% quarter-over-quarter from $157.4 million in Q4 2017, and down 15.18% on a YoY basis from $157.4 million in Q4 2017.
Biogen (BIIB) Finished Goods (2010 - 2018) Analysis & Trends
Biogen's Finished Goods history runs 9 years deep, the most recent figure standing at $133.5 million for Q4 2018.
- In Q4 2018, Finished Goods fell 15.18% year-over-year to $133.5 million; the TTM figure through Dec 2018 stood at $133.5 million (down 15.18% YoY), while the FY2018 annual figure was $133.5 million, down 15.18% from the prior year.
- Finished Goods was $133.5 million for Q4 2018 at Biogen, down from $157.4 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $170.3 million in Q4 2016 to a low of $133.5 million in Q4 2018.
- Historically, Finished Goods has averaged $153.7 million across 5 years, with a median of $157.4 million in 2017.
- The sharpest annual moves came in 2014 and 2018: Finished Goods soared 51.2% in 2014, then dropped 15.18% in 2018.
- A 5-year view of Finished Goods shows it stood at $164.2 million in 2014, then slipped by 12.91% to $143.0 million in 2015, then gained by 19.09% to $170.3 million in 2016, then dropped by 7.57% to $157.4 million in 2017, then retreated by 15.18% to $133.5 million in 2018.
- The last three Finished Goods figures came in at $133.5 million (Q4 2018), $157.4 million (Q4 2017), and $170.3 million (Q4 2016), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 133.50 Mn |
| Dec 31, 2017 | 157.40 Mn |
| Dec 31, 2016 | 170.30 Mn |
| Dec 31, 2015 | 143.00 Mn |
| Dec 31, 2014 | 164.20 Mn |
| Dec 31, 2013 | 108.60 Mn |
| Mar 31, 2013 | 120.70 Mn |
| Dec 31, 2012 | 100.70 Mn |
| Jun 30, 2012 | 103.20 Mn |
| Mar 31, 2012 | 83.30 Mn |
| Dec 31, 2011 | 73.60 Mn |
| Dec 31, 2010 | 230.10 Mn |